We have built a large, expert team to design and manage our clinical trials, the vital and lengthy phase following discovery and preclinical development.
Our Clinical Development and Regulatory Affairs group has more than 400 team members, including many with doctoral degrees and years of pharmaceutical-industry experience.
Peter Powchik, M.D.
Senior Vice President, Clinical Development
Bola Akinlade, M.D., M.B.A., F.A.C.P.
Executive Director, Clinical Sciences
Ned Braunstein, M.D.
Senior Vice President, Regulatory Affairs
Ingrid Adamsons, M.D., M.P.H.
VP Pharmacovigilance and Risk Management
Graeme Currie, Ph.D.
VP Clinical Project Management and Operations
Israel Lowy, M.D., Ph.D.
VP Clinical Sciences Translational Science and of Oncology
Daniel Matarazzo, M.B.A.
Senior Director Clinical Finance
Scott Mellis, M.D., Ph.D.
VP Clinical Sciences Translational Medicine
Robert Pordy, M.D., FACP
VP Regulatory Development and Medical Safety
Yuhwen Soo, Ph.D.
VP Biostatistics and Data Management
Catherine Stehman-Breen, M.D., M.S.
VP Clinical Sciences
Beate Stych, M.D.
VP Medical Affairs
Janet van Adelsberg, M.D.
Senior Director, Immunology and Inflammation
Robert Vitti, M.D., M.B.A.
VP Clinical Sciences Ophthalmology
This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.